Abstract
Diabetes mellitus is an increasing public health problem in the world. Type 2 diabetes is the most common type of diabetes whose complications contribute to its high death rate. It seriously impacts healthcare systems and patients' quality of life. Therefore, effective measures and new treatment strategies are needed to solve this increasingly serious global problem. In recent years, inhibition of dipeptidyl peptidase IV (DPP-IV) has emerged as a new treatment option for Type 2 diabetes. This article reviews various plant DPP-IV inhibitors that showed inhibition toward enzyme as a major target for the management of Type 2 diabetes. These studies can contribute to the future development of DPP-IV inhibitors as drugs.
Keywords:
DPP-IV inhibitors; Type 2 diabetes; antidiabetic; dipeptidyl peptidase IV.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anacardiaceae / chemistry
-
Anacardiaceae / metabolism
-
Biological Products / chemistry
-
Biological Products / isolation & purification
-
Biological Products / pharmacology
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Diabetes Mellitus, Type 2 / pathology
-
Dipeptidyl Peptidase 4 / chemistry*
-
Dipeptidyl Peptidase 4 / metabolism
-
Dipeptidyl-Peptidase IV Inhibitors / chemistry*
-
Dipeptidyl-Peptidase IV Inhibitors / isolation & purification
-
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
-
Humans
-
Hypoglycemic Agents / chemistry*
-
Hypoglycemic Agents / isolation & purification
-
Hypoglycemic Agents / therapeutic use
-
Rhizophoraceae / chemistry
-
Rhizophoraceae / metabolism
-
Smilax / chemistry
-
Smilax / metabolism
-
Vigna / chemistry
-
Vigna / metabolism
Substances
-
Biological Products
-
Dipeptidyl-Peptidase IV Inhibitors
-
Hypoglycemic Agents
-
Dipeptidyl Peptidase 4